Day 1

Introductory remarks

Professor Laura J.V. Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP)

Session 1 – Keynote presentation

Chair: Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP)

  • The politics of drug development
    • Dame Sally Davies, UK Government Special Envoy on Antimicrobial Resistance, UK Department of Health and Social Care

Session 2 – Early Drug Discovery

Chair: Dr Marcus Miethke, Scientist & Project Manager, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany

  • In vitro and in vivo profiling of natural products from Myxobacteria towards the development of anti-infective drugs
    • Dr Jennifer Herrmann, Scientist, HIPS/HZI & DZIF
  • Gram-negative antibacterial discovery – looking for the high-hanging fruits
    • Dr Benjamin Blasco Discovery Senior Project Manager, GARDP, Switzerland
  • Microbial natural products: still an untapped source for novel antibiotic discovery
    • Dr Olga Genilloud, Scientific Director, Fundación MEDINA 

Session 3 – Pre-clinical antimicrobial development

Chair: Professor Alasdair MacGowan, Consultant in Infection at North Bristol NHS Trust & Professor of Antimicrobial Therapeutics at the University of Bristol, UK

  • From old drugs to new: Repurposing old antibiotics to combat antimicrobial resistance
    • Dr Christopher Darlow, MRC Clinical Research Fellow, Institute of Systems, Molecular & Integrative Biology, University of Liverpool 
  • Linking PK and PD studies in animals with PBPK/PD modelling – in silico from mouse to human
    • Dr Katharina Rox, Postdoc, HZI/DZIF 
  • Pre-clinical development of Corallopyronin A – a novel natural product active against helminths, STIs and Staphylococci
    • Professor Achim Hoerauf, Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn/DZIF 

Session 4 – Poster session

Chair: Prof Dr Rolf Müller, Head of Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) & Department Microbial Natural Products (MINS), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Germany

  • Clinical outcomes in Carbapenem resistant Enterobacteriaceae infections treated with Ceftazidime-avibactam: A single centre observational study
    • Balram Rathish, Clinical Fellow in Infectious Diseases, Aster Medcity, Kochi, India
  • 5-Fluorouracil – mechanism of action and resistance mechanisms
    • Sara Henderson , Research associate, Norwich Medical School, UEA, UK
  • Worse than a stroke? Long-term outcome and risk factors for late mortality in Gram-negative bacteraemia
    • Ioannis Baltas, Foundation Year 3 Doctor, Frimley Health NHS Foundation Trust, UK
  • Genomic and Bioassay-guided Approaches for Discovery of Novel Antibiotics from Marine Bacteria
    • Matthias Agbo, University of Nigeria, Nsukka, Nigeria
  • Epigenetic Mode of Bacterial Drug Resistance
    • Guru Prasad Manderwad, Kamineni Academy of Medical Sciences and Research Centre, India
  • Ecm16 protein confers resistance against the DNA intercalator antibiotic echinomycin
    • Priyanka Gade, University of Texas at El Paso, US
  • Genomic analysis of Colistin resistance in Carbapenem-Resistant Enterobacterales and XDR Klebsiella pneumoniae
    • Raunak Bir, Senior Resident Doctor, All India Institute of Medical Sciences, New Delhi, India
  • Formulation, Characterization and Evaluation of Wog19-Loaded and Wog19 +Chloroquine-Loaded Solid Lipid Nanoparticles for the Treatment of Malaria Caused by Sensitive and Resistant Strains of P. berghei
    • Samuel Uzondu, Lecturer /Researcher, NanoMalaria Research Unit, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka. Nigeria
  • The Three Ages of Antibiotics
    • Emily Mayhew, Historian in residence, Dept of Bioengineering, Imperial College London, UK

Day one closing remarks

Professor William Hope, University of Liverpool, UK

Day 2

Introductory remarks

Professor William Hope, University of Liverpool, UK

Session 5 – Learning lessons: clinical trials

Chair: Professor Mike Sharland, Consultant in paediatric infectious diseases, St George’s University Hospitals NHS Foundation Trust, UK

  • Lessons for Clinical Research from COVID-19
    • Professor Andy Ustianowski, Principal Clinical Research Lead, North Manchester General Hospital, UK
  • Innovative design of clinical trials
    • Professor Sarah Walker, University College London, UK
  • Developing a TB drug in academia: The BTZ043 from lead candidate to pivotal clinical trials – lesson learned from a complex endeavour
    • Professor Dr Michael Hoelscher, Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Germany

Session 6 – Non-traditional approaches and challenges

Chair: Dr Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents (CEFAIA), Austria

  • The non-traditional treatment pipeline
    • Dr Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents (CEFAIA), Austria
  • Elastase inhibitor
    • Dr Martin Everett, Chief Scientific Officer, Antabio, UK
  • Therapeutic Development of Bacteriophages
    • Professor Martha Clokie, Professor of Microbiology, University of Leicester, UK

Session 7 – Keynote presentation

Chair: Dr Jean-Pierre Paccaud, Director, Business Development and Corporate Strategy, Global Antibiotic R&D Partnership (GARDP), Switzerland

  • Facilitators and barriers to securing access to new and old antibiotics
    • Dr Christine Ardal, Senior Advisor, Institute of Public Health, Norway

Session 8 – Panel discussion: Careers in drug development and antimicrobial chemotherapy

Chair: Professor Laura J.V. Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) 

  • Dr Olga Genilloud, Scientific Director, Fundación MEDINA
  • Dr Sumathi Nambiar, Director, Division of Anti-Infective (DAI), FDA
  • Prof Dr Rolf Müller, Head of Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) & Department Microbial Natural Products (MINS), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
  • Dr Martin Everett, Chief Scientific Officer, Antabio

Closing remarks

Professor Laura Piddock, Director of Scientific Affairs, GARDP